Marine Pharmaceuticals Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, Germany, UK, China - Size and Forecast 2024-2028

Published: Nov 2023 Pages: 98 SKU: IRTNTR70227

Marine Pharmaceuticals Market 2024-2028

The global marine pharmaceuticals market size is estimated to grow by USD 1.95 billion at a CAGR of 8.63% between 2023 and 2028. 

Marine ecosystems are abounding with an extensive array of unique and often undiscovered marine organisms. These organisms produce a wide variety of bioactive compounds that have the potential for pharmaceutical applications. The diverse marine biodiversity serves as a source of novel compounds, which are valuable for drug discovery and development.  Moreover, the exploration and study of marine biodiversity through bioprospecting have become an essential component of marine pharmaceutical research. This systematic search helps identify and isolate bioactive compounds. Certain regions of the world, such as coral reefs and deep-sea ecosystems, are biodiversity hotspots that are of particular interest to the marine pharmaceutical industry. Thus, the presence of rich marine biodiversity will drive the growth of the marine pharmaceuticals market during the forecast period.

Technavio has segmented the market into  Product, Type, and Geography 

  • The product segment is classified into oncology, cardiovascular, anti-infectives, and others
  • The type segment is classified into health supplements and drugs
  • The geography segment includes key regions such as North America, Europe, Asia, and Rest of World (ROW)

It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historical data from 2018 - 2022, besides analyzing the current market scenario.

What will be the Size of the Marine Pharmaceuticals Market During the Forecast Period?

To learn more about this report, Request Free Sample

Marine Pharmaceuticals Market Segmentation by Product, Type and Geography Analysis

Product Analysis 

Oncology

The market share growth by the oncology segment will be significant during the forecast period. Cancer is among the most frequent causes of death across the globe. Although tremendous progress is underway in cancer therapy R&D, an urgent need for novel oncology drugs still exists. Currently, the development of checkpoint inhibitors is gaining momentum; these are therapeutic antibodies that facilitate or enhance an immune response against tumour cells. 

Get a glance at the market contribution of various segments Download PDF Sample

The oncology segment was the largest and was valued at USD 1.44 billion in 2018. The growing number of cancer cases across the world has resulted in an increase in the need for research to diagnose and treat cancer. As per data from clinicaltrials.gov, as of January 2022, there were more than 6700 active clinical studies on cancer in the US. Thus, the demand for marine pharmaceuticals to treat various types of cancer is expected to increase during the forecast period. The growth will also be fueled by the increasing availability and expansion of the indications by the US FDA. For instance, ADCETRIS was approved by the US FDA as well as the European Commission (EC) for relapsed systemic anaplastic large cell lymphoma (sALCL), relapsed Hodgkin lymphoma, and other CD30 expressing malignancies. All these factors will drive the growth of the oncology segment of the global marine pharmaceuticals market during the forecast period.

Type Analysis 

Health supplements

Marine-derived compounds have demonstrated the potential to act as antibiotics and antimicrobial agents, making them valuable for treating bacterial and fungal infections. They may offer solutions to combat antibiotic-resistant pathogens. Marine-derived compounds exhibit anti-inflammatory properties, which can be beneficial in the development of drugs for conditions involving inflammation, such as arthritis and autoimmune diseases. Marine pharmaceuticals have shown promise in the development of anticancer drugs. Marine organisms have produced natural products with antibacterial, antifungal, and antiparasitic activities, which can be used to develop anti-infective agents. Thus, the use of marine pharmaceuticals as antibiotics and antimicrobial agents, anticancer agents, immunomodulators, anticoagulants, and blood thinners will promote the growth of the drug segment and propel the growth of the global marine pharmaceuticals market during the forecast period.

Drugs

Omega-3 fatty acids derived from marine sources such as fish oil are commonly used as health supplements. These supplements are known for their potential to support cardiovascular health, reduce inflammation, and improve cognitive function. Astaxanthin, a carotenoid found in marine microorganisms and certain seafood, is available as a supplement. It is believed to have antioxidant properties that can support eye health, skin health, and joint function. Marine compounds with anti-inflammatory properties may be used in supplements to reduce inflammation and support immune function. Supplements containing marine collagen, astaxanthin, and other marine-derived compounds are used to support skin health, including hydration and skin ageing. Thus, these benefits of marine will promote the growth of the segment and drive the growth of the marine pharmaceuticals market during the forecast period.

Regional Analysis

For more insights about the market share of various regions Download PDF Sample now!

North America is estimated to contribute 41% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. North America holds the dominating position in the global marine pharmaceuticals market largely due to the significant prevalence of diseases in the region. In recent years, the increasing prevalence of diseases such as cancer, cardiovascular diseases, and Alzheimer's among individuals in North America is fueling the demand for treatment of these diseases to offer better patient care. The coastal regions of North America, including the Atlantic and Pacific coasts, are home to a diverse range of marine organisms that can serve as sources for novel pharmaceutical compounds. Government agencies in North America, such as the National Oceanic and Atmospheric Administration (NOAA) and the National Institutes of Health (NIH), often provide funding and support for marine biotechnology and pharmaceutical research.

In addition, the high prevalence of cancer in North America will increase the demand for oncology products from marine sources. The market growth will also be supported by product approvals. For instance, ADCETRIS (brentuximab vedotin) received approval from the US FDA for the treatment of primary cutaneous anaplastic large cell lymphoma (pcALCL) in individuals who received systemic therapy previously. All these factors will increase the demand for marine pharmaceuticals in North America during the forecast period.

COVID Recovery Analysis

In 2020, the COVID-19 pandemic negatively impacted the regional marine pharmaceuticals market. However, in H2 2021, the introduction of COVID-19 vaccines led to a decrease in the number of COVID-19 cases in the region, which led to the easing of the lockdown restrictions. This has resulted in the resumption of supply chain operations, which has resulted in the availability of marine pharmaceutical drugs for the treatment of different forms of carcinoma, pain, and CVD. Moreover, there is a growing awareness of the need for sustainable and environmentally responsible practices. The marine pharmaceuticals industry in North America is likely to emphasize responsible sourcing and conservation efforts. These factors will drive the growth of the regional marine pharmaceuticals market during the forecast period.

Buy Full Report Now

Key Marine Pharmaceuticals Market Players 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:

BASF SE - The company offers marine pharmaceuticals which provide quality marine-based ingredients and customized products under the brand Equateq Ltd.

  • Abbott Laboratories
  • BeyondSpring Inc.
  • BioMarin Pharmaceutical Inc.
  • Bristol Myers Squibb Co.
  • Croda International Plc
  • DEKRA SE
  • EID Parry India Ltd.,
  • Eisai Co. Ltd.
  • GFR Pharma,
  • GlaxoSmithKline Plc
  • Jazz Pharmaceuticals Plc
  • Koninklijke DSM NV
  • MARINE LIFESCIENCES,
  • Merck KGaA
  • Pfizer Inc.
  • PharmaMar SA
  • Roquette Freres SA
  • TerSera Therapeutics LLC
  • ZELNOVA ZELTIA S.A.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Marine Pharmaceuticals Market: Key Drivers, Trends, Challenges, and Customer Landscape

There are multiple factors influencing market growth. Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. 

Key Marine Pharmaceuticals Market Drivers

Rising consumer demand for natural products is notably driving the driving market growth. Consumer preferences are shifting toward natural and environmentally friendly products in various industries, including pharmaceuticals. Marine-derived pharmaceuticals, which are sourced from the ocean and are often considered natural products, align with these preferences. Natural products are often perceived as safer and gentler on the body compared with synthetic drugs. The use of marine-derived compounds in pharmaceuticals can offer a perception of safety and efficacy, appealing to health-conscious consumers.

In addition, marine-derived compounds often have applications beyond pharmaceuticals, such as cosmetics, dietary supplements, and functional foods. This diversification of marine products allows consumers to access the benefits of marine-derived compounds. Thus, the rising consumer demand for natural products will impel the growth of the global marine pharmaceuticals market during the forecast period.

Significant Marine Pharmaceuticals Market Trends

Research for anti-inflammatory compounds from marine sources is an emerging trend shaping the market growth.  Inflammation is a well-regulated process in the human body. Any disturbance in the process of the inflammatory response can lead to chronic inflammation and prove fatal in some cases. Inflammation can lead to disorders such as rheumatoid arthritis, multiple sclerosis, and inflammatory bowel diseases. Marine invertebrates are sources of prime importance for new pharmaceutical products. The diterpenoids, the secondary metabolites present in them, exhibit significant anti-inflammatory properties. 

However, several programs for drug discovery and development are focused on the identification of bioactive compounds from marine sources. The compounds having strong anti-inflammatory activity are expected to be discovered, which will enhance the global marine pharmaceuticals market during the forecast period.

Major Marine Pharmaceuticals Market Challenges

Difficulties in drug development are a significant challenge hindering market growth.  The lack of success in the development of early-stage candidates leads to very few late-stage pre-clinical candidates, which has been one of the major hurdles in drug discovery research from natural products. The problem is often termed as crossing the valley of death. A large number of marine pharmaceutical leads are published in scientific literature as exciting leads for a pharmaceutical product. The requirements for the advancement of an agent to the next level include the determination of the site of the mechanism of action, formulation as well and in-vivo evaluations in animal models to determine its efficacy and toxicity.

Furthermore, It is essential to establish a relationship between structure and activity, characterization of pharmaceutical properties, and pharmacokinetic parameters, along with improvements in medicinal chemistry. Thus, the difficulties in drug development will inhibit the growth of the global marine pharmaceuticals market during the forecast period.

Buy Now Full Report

Key Marine Pharmaceuticals Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Marine Pharmaceuticals Market Customer Landscape

Segment Overview

The marine pharmaceuticals market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2018 to 2028. 

  • Product Outlook
    • Oncology
    • Cardiovascular
    • Anti-infectives
    • Others
  • Type Outlook
    • Health supplements
    • Drugs
  • Region Outlook
    • North America
      • The U.S.
      • Canada
    • Europe
      • The U.K.
      • Germany
      • France
      • Rest of Europe
    • Asia
      • China
      • India
    • Rest of World (ROW)
      • Brazil
      • Argentina 
      • Australia

Marine Pharmaceuticals Market Scope

Report Coverage

Details

Page number

176

Base year

2023

Historic period

2018-2022

Forecast period

2024-2028

Growth momentum & CAGR

Accelerate at a CAGR of 8.63%

Market Growth 2024-2028

USD 1.95 billion

Market structure

Fragmented

YoY growth 2023-2024(%)

7.45

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 41%

Key countries

US, Canada, Germany, UK, and China

Competitive landscape

Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks

Key companies profiled

Abbott Laboratories, BASF SE, BeyondSpring Inc., BioMarin Pharmaceutical Inc., Bristol Myers Squibb Co., Croda International Plc, DEKRA SE, EID Parry India Ltd., Eisai Co. Ltd., GFR Pharma, GlaxoSmithKline Plc, Jazz Pharmaceuticals Plc, Koninklijke DSM NV, MARINE LIFESCIENCES, Merck KGaA, Pfizer Inc., PharmaMar SA, Roquette Freres SA, TerSera Therapeutics LLC, and ZELNOVA ZELTIA S.A.

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period. 

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Download Sample PDF at your Fingertips

What are the Key Data Covered in this Marine Pharmaceuticals Market Research Report?

  • CAGR of the market during the forecast period
  • Detailed information on factors that will drive the growth of the marine pharmaceuticals market between 2024 and 2028
  • Precise estimation of the marine pharmaceuticals market size and its contribution of the market in focus to the parent market
  • Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria 
  • Companies landscape comparing criticality of inputs and factors of differentiation
  • Exclusive Matrix on companies position and classification
  • Accurate predictions about upcoming trends and changes in consumer behavior
  • Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
  • A thorough analysis of the market’s competitive landscape and detailed information about companies
  • Comprehensive analysis of factors that will challenge the growth of marine pharmaceuticals market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Product
    • Exhibit 06: Executive Summary – Chart on Market Segmentation by Type
    • Exhibit 07: Executive Summary – Chart on Incremental Growth
    • Exhibit 08: Executive Summary – Data Table on Incremental Growth
    • Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 10: Parent market
    • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 13: Market segments
  • 3.3 Market size 2023
    • 3.4 Market outlook: Forecast for 2023-2028
      • Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
      • Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
      • Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
      • Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

    4 Historic Market Size

    • 4.1 Global cancer immunotherapy market 2017 - 2021
      • Exhibit 18: Historic Market Size – Data Table on global cancer immunotherapy market 2017 - 2021 ($ million)
    • 4.2 Type Segment Analysis 2017 - 2021
      • Exhibit 19: Historic Market Size – Type Segment 2017 - 2021 ($ million)
    • 4.3 Application Segment Analysis 2017 - 2021
      • Exhibit 20: Historic Market Size – Application Segment 2017 - 2021 ($ million)
    • 4.4 Geography Segment Analysis 2017 - 2021
      • Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million)
    • 4.5 Country Segment Analysis 2017 - 2021
      • Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million)

    5 Five Forces Analysis

    • 5.1 Five forces summary
      • Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
    • 5.2 Bargaining power of buyers
      • Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2023 and 2028
    • 5.3 Bargaining power of suppliers
      • Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2023 and 2028
    • 5.4 Threat of new entrants
      • Exhibit 26: Threat of new entrants – Impact of key factors in 2023 and 2028
    • 5.5 Threat of substitutes
      • Exhibit 27: Threat of substitutes – Impact of key factors in 2023 and 2028
    • 5.6 Threat of rivalry
      • Exhibit 28: Threat of rivalry – Impact of key factors in 2023 and 2028
    • 5.7 Market condition
      • Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

    6 Market Segmentation by Product

    • 6.1 Market segments
      • Exhibit 30: Chart on Product - Market share 2023-2028 (%)
      • Exhibit 31: Data Table on Product - Market share 2023-2028 (%)
    • 6.2 Comparison by Product
      • Exhibit 32: Chart on Comparison by Product
      • Exhibit 33: Data Table on Comparison by Product
    • 6.3 Oncology - Market size and forecast 2023-2028
      • Exhibit 34: Chart on Oncology - Market size and forecast 2023-2028 ($ million)
      • Exhibit 35: Data Table on Oncology - Market size and forecast 2023-2028 ($ million)
      • Exhibit 36: Chart on Oncology - Year-over-year growth 2023-2028 (%)
      • Exhibit 37: Data Table on Oncology - Year-over-year growth 2023-2028 (%)
    • 6.4 Cardiovascular - Market size and forecast 2023-2028
      • Exhibit 38: Chart on Cardiovascular - Market size and forecast 2023-2028 ($ million)
      • Exhibit 39: Data Table on Cardiovascular - Market size and forecast 2023-2028 ($ million)
      • Exhibit 40: Chart on Cardiovascular - Year-over-year growth 2023-2028 (%)
      • Exhibit 41: Data Table on Cardiovascular - Year-over-year growth 2023-2028 (%)
    • 6.5 Anti-infectives - Market size and forecast 2023-2028
      • Exhibit 42: Chart on Anti-infectives - Market size and forecast 2023-2028 ($ million)
      • Exhibit 43: Data Table on Anti-infectives - Market size and forecast 2023-2028 ($ million)
      • Exhibit 44: Chart on Anti-infectives - Year-over-year growth 2023-2028 (%)
      • Exhibit 45: Data Table on Anti-infectives - Year-over-year growth 2023-2028 (%)
    • 6.6 Others - Market size and forecast 2023-2028
      • Exhibit 46: Chart on Others - Market size and forecast 2023-2028 ($ million)
      • Exhibit 47: Data Table on Others - Market size and forecast 2023-2028 ($ million)
      • Exhibit 48: Chart on Others - Year-over-year growth 2023-2028 (%)
      • Exhibit 49: Data Table on Others - Year-over-year growth 2023-2028 (%)
    • 6.7 Market opportunity by Product
      • Exhibit 50: Market opportunity by Product ($ million)
      • Exhibit 51: Data Table on Market opportunity by Product ($ million)

    7 Market Segmentation by Type

    • 7.1 Market segments
      • Exhibit 52: Chart on Type - Market share 2023-2028 (%)
      • Exhibit 53: Data Table on Type - Market share 2023-2028 (%)
    • 7.2 Comparison by Type
      • Exhibit 54: Chart on Comparison by Type
      • Exhibit 55: Data Table on Comparison by Type
    • 7.3 Health supplements - Market size and forecast 2023-2028
      • Exhibit 56: Chart on Health supplements - Market size and forecast 2023-2028 ($ million)
      • Exhibit 57: Data Table on Health supplements - Market size and forecast 2023-2028 ($ million)
      • Exhibit 58: Chart on Health supplements - Year-over-year growth 2023-2028 (%)
      • Exhibit 59: Data Table on Health supplements - Year-over-year growth 2023-2028 (%)
    • 7.4 Drugs - Market size and forecast 2023-2028
      • Exhibit 60: Chart on Drugs - Market size and forecast 2023-2028 ($ million)
      • Exhibit 61: Data Table on Drugs - Market size and forecast 2023-2028 ($ million)
      • Exhibit 62: Chart on Drugs - Year-over-year growth 2023-2028 (%)
      • Exhibit 63: Data Table on Drugs - Year-over-year growth 2023-2028 (%)
    • 7.5 Market opportunity by Type
      • Exhibit 64: Market opportunity by Type ($ million)
      • Exhibit 65: Data Table on Market opportunity by Type ($ million)

    8 Customer Landscape

    • 8.1 Customer landscape overview
      • Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    9 Geographic Landscape

    • 9.1 Geographic segmentation
      • Exhibit 67: Chart on Market share by geography 2023-2028 (%)
      • Exhibit 68: Data Table on Market share by geography 2023-2028 (%)
    • 9.2 Geographic comparison
      • Exhibit 69: Chart on Geographic comparison
      • Exhibit 70: Data Table on Geographic comparison
    • 9.3 North America - Market size and forecast 2023-2028
      • Exhibit 71: Chart on North America - Market size and forecast 2023-2028 ($ million)
      • Exhibit 72: Data Table on North America - Market size and forecast 2023-2028 ($ million)
      • Exhibit 73: Chart on North America - Year-over-year growth 2023-2028 (%)
      • Exhibit 74: Data Table on North America - Year-over-year growth 2023-2028 (%)
    • 9.4 Europe - Market size and forecast 2023-2028
      • Exhibit 75: Chart on Europe - Market size and forecast 2023-2028 ($ million)
      • Exhibit 76: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
      • Exhibit 77: Chart on Europe - Year-over-year growth 2023-2028 (%)
      • Exhibit 78: Data Table on Europe - Year-over-year growth 2023-2028 (%)
    • 9.5 Asia - Market size and forecast 2023-2028
      • Exhibit 79: Chart on Asia - Market size and forecast 2023-2028 ($ million)
      • Exhibit 80: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
      • Exhibit 81: Chart on Asia - Year-over-year growth 2023-2028 (%)
      • Exhibit 82: Data Table on Asia - Year-over-year growth 2023-2028 (%)
    • 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
      • Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
      • Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
      • Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
      • Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
    • 9.7 US - Market size and forecast 2023-2028
      • Exhibit 87: Chart on US - Market size and forecast 2023-2028 ($ million)
      • Exhibit 88: Data Table on US - Market size and forecast 2023-2028 ($ million)
      • Exhibit 89: Chart on US - Year-over-year growth 2023-2028 (%)
      • Exhibit 90: Data Table on US - Year-over-year growth 2023-2028 (%)
    • 9.8 Germany - Market size and forecast 2023-2028
      • Exhibit 91: Chart on Germany - Market size and forecast 2023-2028 ($ million)
      • Exhibit 92: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
      • Exhibit 93: Chart on Germany - Year-over-year growth 2023-2028 (%)
      • Exhibit 94: Data Table on Germany - Year-over-year growth 2023-2028 (%)
    • 9.9 China - Market size and forecast 2023-2028
      • Exhibit 95: Chart on China - Market size and forecast 2023-2028 ($ million)
      • Exhibit 96: Data Table on China - Market size and forecast 2023-2028 ($ million)
      • Exhibit 97: Chart on China - Year-over-year growth 2023-2028 (%)
      • Exhibit 98: Data Table on China - Year-over-year growth 2023-2028 (%)
    • 9.10 Canada - Market size and forecast 2023-2028
      • Exhibit 99: Chart on Canada - Market size and forecast 2023-2028 ($ million)
      • Exhibit 100: Data Table on Canada - Market size and forecast 2023-2028 ($ million)
      • Exhibit 101: Chart on Canada - Year-over-year growth 2023-2028 (%)
      • Exhibit 102: Data Table on Canada - Year-over-year growth 2023-2028 (%)
    • 9.11 UK - Market size and forecast 2023-2028
      • Exhibit 103: Chart on UK - Market size and forecast 2023-2028 ($ million)
      • Exhibit 104: Data Table on UK - Market size and forecast 2023-2028 ($ million)
      • Exhibit 105: Chart on UK - Year-over-year growth 2023-2028 (%)
      • Exhibit 106: Data Table on UK - Year-over-year growth 2023-2028 (%)
    • 9.12 Market opportunity by geography
      • Exhibit 107: Market opportunity by geography ($ million)
      • Exhibit 108: Data Tables on Market opportunity by geography ($ million)

    10 Drivers, Challenges, and Trends

    • 10.1 Market drivers
      • 10.2 Market challenges
        • 10.3 Impact of drivers and challenges
          • Exhibit 109: Impact of drivers and challenges in 2023 and 2028
        • 10.4 Market trends

          11 Vendor Landscape

          • 11.1 Overview
            • 11.2 Vendor landscape
              • Exhibit 110: Overview on Criticality of inputs and Factors of differentiation
            • 11.3 Landscape disruption
              • Exhibit 111: Overview on factors of disruption
            • 11.4 Industry risks
              • Exhibit 112: Impact of key risks on business

            12 Vendor Analysis

            • 12.1 Vendors covered
              • Exhibit 113: Vendors covered
            • 12.2 Market positioning of vendors
              • Exhibit 114: Matrix on vendor position and classification
            • 12.3 BASF SE
              • Exhibit 115: BASF SE - Overview
              • Exhibit 116: BASF SE - Business segments
              • Exhibit 117: BASF SE - Key news
              • Exhibit 118: BASF SE - Key offerings
              • Exhibit 119: BASF SE - Segment focus
            • 12.4 BeyondSpring Inc.
              • Exhibit 120: BeyondSpring Inc. - Overview
              • Exhibit 121: BeyondSpring Inc. - Product / Service
              • Exhibit 122: BeyondSpring Inc. - Key offerings
            • 12.5 BioMarin Pharmaceutical Inc.
              • Exhibit 123: BioMarin Pharmaceutical Inc. - Overview
              • Exhibit 124: BioMarin Pharmaceutical Inc. - Product / Service
              • Exhibit 125: BioMarin Pharmaceutical Inc. - Key offerings
            • 12.6 Bristol Myers Squibb Co.
              • Exhibit 126: Bristol Myers Squibb Co. - Overview
              • Exhibit 127: Bristol Myers Squibb Co. - Product / Service
              • Exhibit 128: Bristol Myers Squibb Co. - Key news
              • Exhibit 129: Bristol Myers Squibb Co. - Key offerings
            • 12.7 Croda International Plc
              • Exhibit 130: Croda International Plc - Overview
              • Exhibit 131: Croda International Plc - Business segments
              • Exhibit 132: Croda International Plc - Key news
              • Exhibit 133: Croda International Plc - Key offerings
              • Exhibit 134: Croda International Plc - Segment focus
            • 12.8 Eisai Co. Ltd.
              • Exhibit 135: Eisai Co. Ltd. - Overview
              • Exhibit 136: Eisai Co. Ltd. - Business segments
              • Exhibit 137: Eisai Co. Ltd. - Key offerings
              • Exhibit 138: Eisai Co. Ltd. - Segment focus
            • 12.9 GFR Pharma
              • Exhibit 139: GFR Pharma - Overview
              • Exhibit 140: GFR Pharma - Product / Service
              • Exhibit 141: GFR Pharma - Key offerings
            • 12.10 GlaxoSmithKline Plc
              • Exhibit 142: GlaxoSmithKline Plc - Overview
              • Exhibit 143: GlaxoSmithKline Plc - Business segments
              • Exhibit 144: GlaxoSmithKline Plc - Key news
              • Exhibit 145: GlaxoSmithKline Plc - Key offerings
              • Exhibit 146: GlaxoSmithKline Plc - Segment focus
            • 12.11 Jazz Pharmaceuticals Plc
              • Exhibit 147: Jazz Pharmaceuticals Plc - Overview
              • Exhibit 148: Jazz Pharmaceuticals Plc - Product / Service
              • Exhibit 149: Jazz Pharmaceuticals Plc - Key news
              • Exhibit 150: Jazz Pharmaceuticals Plc - Key offerings
            • 12.12 Koninklijke DSM NV
              • Exhibit 151: Koninklijke DSM NV - Overview
              • Exhibit 152: Koninklijke DSM NV - Business segments
              • Exhibit 153: Koninklijke DSM NV - Key news
              • Exhibit 154: Koninklijke DSM NV - Key offerings
              • Exhibit 155: Koninklijke DSM NV - Segment focus
            • 12.13 Merck KGaA
              • Exhibit 156: Merck KGaA - Overview
              • Exhibit 157: Merck KGaA - Business segments
              • Exhibit 158: Merck KGaA - Key news
              • Exhibit 159: Merck KGaA - Key offerings
              • Exhibit 160: Merck KGaA - Segment focus
            • 12.14 Pfizer Inc.
              • Exhibit 161: Pfizer Inc. - Overview
              • Exhibit 162: Pfizer Inc. - Product / Service
              • Exhibit 163: Pfizer Inc. - Key news
              • Exhibit 164: Pfizer Inc. - Key offerings
            • 12.15 PharmaMar SA
              • Exhibit 165: PharmaMar SA - Overview
              • Exhibit 166: PharmaMar SA - Business segments
              • Exhibit 167: PharmaMar SA - Key offerings
              • Exhibit 168: PharmaMar SA - Segment focus
            • 12.16 TerSera Therapeutics LLC
              • Exhibit 169: TerSera Therapeutics LLC - Overview
              • Exhibit 170: TerSera Therapeutics LLC - Product / Service
              • Exhibit 171: TerSera Therapeutics LLC - Key offerings
            • 12.17 ZELNOVA ZELTIA S.A.
              • Exhibit 172: ZELNOVA ZELTIA S.A. - Overview
              • Exhibit 173: ZELNOVA ZELTIA S.A. - Product / Service
              • Exhibit 174: ZELNOVA ZELTIA S.A. - Key offerings

            13 Appendix

            • 13.1 Scope of the report
              • 13.2 Inclusions and exclusions checklist
                • Exhibit 175: Inclusions checklist
                • Exhibit 176: Exclusions checklist
              • 13.3 Currency conversion rates for US$
                • Exhibit 177: Currency conversion rates for US$
              • 13.4 Research methodology
                • Exhibit 178: Research methodology
                • Exhibit 179: Validation techniques employed for market sizing
                • Exhibit 180: Information sources
              • 13.5 List of abbreviations
                • Exhibit 181: List of abbreviations

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              INFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases

              DATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts

              REPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape

              PURCHASE FULL REPORT OF

              marine pharmaceuticals market market

              Key Questions Answered

              • What are the key global market and the regional market share?
              • What are the revenue-generating key market segments?
              • What are the key factors driving and challenging this market’s growth?
              • Who are the key market vendors and their growth strategies?
              • What are the latest trends influencing the growth of this market?
              • What are the variables influencing the market growth in the primary regions?
              • What are the factors influencing the growth of the parent market?

              Why should you prefer Technavio's market insights report?

              • Off-the-shelf research reports
              • Reports can be tailored to meet the customer's needs
              • Trusted by more than 100 fortune 500 organizations
              • Information about the market's key drivers, trends, and challenges
              • Parent market analysis
              • Every week, 50,000 people visit our subscription platform
              • Detailed vendors report with competitive landscape
              • Covid-19 impact and recovery analysis
              • Data on revenue-generating market segments
              • Details on the market shares of various regions
              • Five-force market analysis